Alvotech Resubmits FDA Applications for Two Key Biosimilars, AVT05 and AVT06
ALVO is trading near its 52-week low of $2.94 (9.9% above the low).
Summary
Alvotech has resubmitted Biologics License Applications (BLAs) to the FDA for AVT05 (Simponi biosimilar) and AVT06 (Eylea biosimilar), addressing prior regulatory concerns and setting a six-month review timeline.
Key Events · Product Development and Regulatory · ALVO
-
FDA Resubmission for AVT05 & AVT06
Alvotech has resubmitted Biologics License Applications (BLAs) to the U.S. FDA for AVT05, a proposed biosimilar to Simponi® and Simponi Aria® (golimumab), and AVT06, a proposed biosimilar to Eylea® (aflibercept) 2 mg.
-
Regulatory Hurdles Addressed
The resubmissions follow Alvotech's response to the FDA's Post-Application Action Letter and observations from a routine cGMP surveillance FDA inspection at its Reykjavik manufacturing facility, completed in May 2026.
-
Six-Month Review Expected
The company expects the FDA to conduct a six-month review of the resubmitted applications, consistent with applicable regulatory timelines.
Analysis · ALVO · Life Sciences
This filing is highly important as Alvotech has successfully addressed the FDA's Post-Application Action Letter and cGMP inspection observations, allowing for the resubmission of two critical biosimilar applications for the U.S. market. The potential approval of AVT05 (golimumab) and especially AVT06 (aflibercept, biosimilar to Eylea, a blockbuster drug) would significantly boost Alvotech's revenue potential and market position, providing a clear path for growth following recent financial reports. The expected six-month review period provides a concrete timeline for investors to anticipate potential approvals.
How filings like this one have moved
In the 30 days to Sep 12, 2026, 35.8% of the 1618 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.19%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ALVO was trading at $3.23 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $979.8M. The 52-week trading range was $2.94 to $11.85. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.